FMS
Fresenius Medical Care Corp
Fresenius Medical Care Corp historical holders
total: 2
Tweedy, Browne Co All Funds (US) Fresenius Medical Care Corp transactions over time
- Total transactions:
- 11
- New positions:
- 1
- Sold out:
- 1
- Added:
- 5
- Reduced:
- 4
- Held since:
- 2021 Q1
- Held for:
- 10 quarters
- Latest activity:
- 2023 Q3
Tweedy, Browne Co All Funds (US) has been an institutional investor in Fresenius Medical Care Corp (FMS) since 2021 Q1. According to 2026 Q1 report, Tweedy, Browne Co All Funds (US) doesn't hold any shares. The fund/company first acquired FMS in 2021 Q1, initially purchasing 530,064 shares. Since the initial investment, Tweedy, Browne Co All Funds (US) has made 10 more transactions in this position.
When did Tweedy, Browne Co All Funds (US) exit their FMS position?
Tweedy, Browne Co All Funds (US) no longer holds Fresenius Medical Care Corp (FMS). They sold off their entire position in 2023 Q3, closing out an investment that began in 2021 Q1.
When did Tweedy, Browne Co All Funds (US) first invest in FMS?
Tweedy, Browne Co All Funds (US) first invested in Fresenius Medical Care Corp (FMS) in 2021 Q1 at the reported quarter-end price of $36.88 per share, acquiring 530,064 shares in their initial purchase.
What is Tweedy, Browne Co All Funds (US)'s average cost basis for FMS?
Based on historical transaction data, Tweedy, Browne Co All Funds (US)'s estimated cost basis for Fresenius Medical Care Corp (FMS) is approximately $35.94 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $35.94
- Weighted AVG sell price:
- $18.93
FMS transactions history by Tweedy, Browne Co All Funds (US)
11 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2023 Q3
|
0.00%
|
0
|
$23.93
|
|
-100% (-339,637)
|
-0.43%
|
|
2023 Q2
|
0.43%
|
339,637
|
$23.93
|
$8,128,000
|
-1.14% (-3,922)
|
-0.01%
|
|
2023 Q1
|
0.40%
|
343,559
|
$21.26
|
$7,304,000
|
+1.37% (+4,647)
|
+0.01%
|
|
2022 Q4
|
0.29%
|
338,912
|
$16.34
|
$5,538,000
|
-66.21% (-664,124)
|
-0.48%
|
|
2022 Q3
|
0.62%
|
1,003,036
|
$14.04
|
$14,083,000
|
-1.32% (-13,404)
|
-0.01%
|
|
2022 Q2
|
1.04%
|
1,016,440
|
$24.94
|
$25,350,000
|
-1.02% (-10,495)
|
-0.01%
|
|
2022 Q1
|
1.12%
|
1,026,935
|
$33.68
|
$34,587,000
|
+0.10% (+990)
|
+0%
|
|
2021 Q4
|
1.06%
|
1,025,945
|
$32.46
|
$33,302,000
|
+20.74% (+176,223)
|
+0.18%
|
|
2021 Q3
|
0.99%
|
849,722
|
$34.97
|
$29,715,000
|
+40.46% (+244,758)
|
+0.29%
|
|
2021 Q2
|
0.71%
|
604,964
|
$41.57
|
$25,148,000
|
+14.13% (+74,900)
|
+0.09%
|
|
2021 Q1
|
0.57%
|
$36.88
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.